Meeting
2015 ASCO Annual Meeting
A phase I trial of intravenous liposomal irinotecan in patients with recurrent high-grade gliomas.
Authors
Jennifer Leigh Clarke
UC San Francisco, San Francisco, CA
Jennifer Leigh Clarke , Annette M Molinaro , Ashley A DeSilva , Jane E Rabbitt , Daryl C. Drummond , Susan Marina Chang , Nicholas A. Butowski , Michael Prados
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT00734682
Citation
J Clin Oncol 33, 2015 (suppl; abstr 2029)
DOI
10.1200/jco.2015.33.15_suppl.2029
Abstract #
2029
Poster Bd #
18
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Phase 1 study of indenoisoquinoline LMP744 in adults with relapsed solid tumors and lymphomas.
First Author: Brian Ko
Poster
2023 ASCO Annual Meeting
A pilot clinical study of oral irinotecan HCl (VAL-413) in patients with recurrent pediatric solid tumors.
First Author: Jeffrey A. Bacha
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Phase 1 study of nanoliposomal irinotecan in combination with trifluridine/tipiracil in refractory solid tumors.
First Author: Li-Yuan Bai
Poster
2021 ASCO Annual Meeting
Phase 1 study of pevonedistat (MLN4924) a NEDD8 activating enzyme inhibitor, in combination with temozolomide (TMZ) and irinotecan (IRN) in pediatric patients with recurrent or refractory solid tumors (ADVL1615).
First Author: Jennifer Foster